will promote bulk drug parks for financing common infrastructure facilities in three such facilities with the financial investment of rs 3000 crore in the next five years jain saidsecondly rs 7000 crore have been allocated for production linked incentive pli scheme for promotion of domestic manufacturing of critical ksmsdrug intermediates and apis in the country he addedgoing forward the execution of the policy on the ground will be important to accelerate the process and this step over a period of time help to provide health security jain notedipa represents 24 research based pharmaceutical companies including sun pharma dr reddys laboratories lupin cipla glenmark piramal cadila and wockhardt among otherscollectively these firms account for 80 per cent of the countrys exports of drugs and pharmaceuticals and service over 57 per cent of the domestic market